130 related articles for article (PubMed ID: 29168243)
1. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
Di Francesco T; Philipp E; Borchard G
Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
[TBL] [Abstract][Full Text] [Related]
2. A robust and easily reproducible protocol for the determination of size and size distribution of iron sucrose using dynamic light scattering.
Di Francesco T; Borchard G
J Pharm Biomed Anal; 2018 Apr; 152():89-93. PubMed ID: 29414023
[TBL] [Abstract][Full Text] [Related]
3. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.
Stein J; Dignass A; Chow KU
Curr Med Res Opin; 2012 Feb; 28(2):241-3. PubMed ID: 22181342
[TBL] [Abstract][Full Text] [Related]
4. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
Pai AB
Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies.
Borchard G; Flühmann B; Mühlebach S
Regul Toxicol Pharmacol; 2012 Nov; 64(2):324-8. PubMed ID: 22951348
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.
Zou P; Tyner K; Raw A; Lee S
AAPS J; 2017 Sep; 19(5):1359-1376. PubMed ID: 28762128
[TBL] [Abstract][Full Text] [Related]
7. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy.
Wu Y; Petrochenko P; Chen L; Wong SY; Absar M; Choi S; Zheng J
Int J Pharm; 2016 May; 505(1-2):167-74. PubMed ID: 27001529
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
Praschberger M; Cornelius C; Schitegg M; Goldenberg H; Scheiber-Mojdehkar B; Sturm B
Pharm Dev Technol; 2015 Mar; 20(2):176-82. PubMed ID: 24219061
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.
Shah RB; Yang Y; Khan MA; Raw A; Yu LX; Faustino PJ
Int J Pharm; 2014 Apr; 464(1-2):46-52. PubMed ID: 24440404
[TBL] [Abstract][Full Text] [Related]
11. Ferumoxytol: an intravenous iron, riskier than iron sucrose.
Prescrire Int; 2013 Sep; 22(141):206. PubMed ID: 24171212
[No Abstract] [Full Text] [Related]
12. Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas.
Beguin Y; Jaspers A
Expert Opin Pharmacother; 2014 Oct; 15(14):2087-103. PubMed ID: 25186219
[TBL] [Abstract][Full Text] [Related]
13. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.
Toblli JE; Cao G; Angerosa M
Biometals; 2015 Apr; 28(2):279-92. PubMed ID: 25609135
[TBL] [Abstract][Full Text] [Related]
14. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
[TBL] [Abstract][Full Text] [Related]
15. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients.
Lee ES; Park BR; Kim JS; Choi GY; Lee JJ; Lee IS
Curr Med Res Opin; 2013 Feb; 29(2):141-7. PubMed ID: 23252876
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Iron Sucrose Therapy in Iron Deficiency Anemia in Antenatal and Postnatal Patients.
Sharma J; Tiwari S
JNMA J Nepal Med Assoc; 2015; 53(198):104-7. PubMed ID: 26994029
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial.
Kochhar PK; Kaundal A; Ghosh P
J Obstet Gynaecol Res; 2013 Feb; 39(2):504-10. PubMed ID: 22925176
[TBL] [Abstract][Full Text] [Related]
20. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Inflamm Allergy Drug Targets; 2012 Feb; 11(1):66-78. PubMed ID: 22309085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
